Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

95 results about "Radioligand" patented technology

A radioligand is a radioactive biochemical substance (in particular, a ligand that is radiolabeled) that is used for diagnosis or for research-oriented study of the receptor systems of the body. In a neuroimaging application the radioligand is injected into the pertinent tissue, or infused into the bloodstream. It binds to its receptor. When the radioactive isotope in the ligand decays it can be measured by positron emission tomography (PET) or single photon emission computed tomography (SPECT). In in vivo systems it is often used to quantify the binding of a test molecule to the binding site of radioligand. The higher the affinity of the molecule the more radioligand is displaced from the binding site and the increasing radioactive decay can be measured by scintillography. This assay is commonly used to calculate binding constant of molecules to receptors.

FAP targeting cyclic peptides and conjugates thereof

Described herein are cyclic peptides targeting fibroblast activation protein (FAP), and their incorporation into compounds for radioligand imaging and therapies, as well as methods and / or uses of such compounds for the imaging, treatment and / or prevention of FAP-implicated diseases and disorders.
Owner:NOVARTIS AG

Cleavable radioligands for targeting cell surface receptors and uses thereof

The present application relates to a compound or a pharmaceutically acceptable salt and / or solvate thereof comprising one or more circulation enhancing groups, one or more target binding groups, one or more chelating groups, at one least cleavable linker and at least one branching group that is at least trivalent. The application further includes a radionuclide complex or a pharmaceutically acceptable salt and / or solvate thereof, comprising a compound of the application or a pharmaceutically acceptable salt and / or solvate thereof, and one or more radionuclides, and to compositions comprising the compound or the complexes. The present application also includes methods of using the compounds, complexes and compositions for targeting and / or killing target cells. For example, the compound includes a compound of Formula I
Owner:FULL-LIFE TECHNOLOGIES UK LTD

Fibroblast activation protein-targeted radioligands with pharmacokinetic modulators

A conjugate of the formula (I) wherein F is a ligand (radical thereof) that binds fibroblast activation protein alpha (FAPα); L is a functionalized linker that binds with F, A, and X; A is a pharmacokinetic extender that binds or associates or binds with a protein in the blood of an animal; and X is chelator; a method of imaging cancer-associated fibroblasts (CAFs) and activated myofibroblasts in a subject; and a method of treating a disease characterized by upregulation of FAPα, such as cancer, in a subject.
Owner:PURDUE RES FOUND

Methods of treating prostate cancer

The present disclosure relates to a method of treating prostate specific membrane antigen (PSMA) positive progressive metastatic castration resistant prostate cancer (mCRPC) by administering a therapeutically effective amount of a PSMA binding radioligand therapy (RLT) agent, preferably [177Lu] Lu-PSMA-617 (lutetium (177Lu) vevovortitide Tailaracetam), to a taxane primarily treated patient whose disease progresses after receiving a second generation ARPI.
Owner:NOVARTIS AG

Combination therapy of benfo-oxythiamine (B-OT) and / or oxythiamine (OT) together with radionuclide therapy in patients with tumors, especially malignancies (cancerous tumors)

Benfo-oxythiamine (B-OT) and / or oxythiamine (OT) are administered as active substances concurrently with ongoing radionuclide therapy (RNT), particularly radioimmunotherapy (RIT) and / or radiopeptide or radioligand or radiopeptide ligand therapy (RLT), in the treatment of patients with tumors, especially malignant tumors. B-OT and / or OT administration is cyclical, meaning that phases of B-OT and / or OT administration ("B-OT / OT administration cycles") alternate with treatment breaks (administration breaks). In each B-OT / OT administration cycle, B-OT and / or OT is administered on one or more consecutive days at a predetermined dose (mg per kg of the patient's body weight). This is followed by a treatment break in which neither B-OT nor OT is administered, and then the next B-OT / OT administration cycle.
Owner:TAVARGENIX GMBH

Targeted radioligand compounds and uses thereof

The present disclosure provides a compound comprising a radiolabeling moiety, a targeting moiety, and a DNA intercalating agent and complexes thereof For example, the present disclosure provides a compound of Formula I or a pharmaceutically acceptable salt and / or solvate thereof. Methods of making and uses thereof, such as cancer theranostic applications, are also included. (I)
Owner:MCMASTER UNIV

Cancer-associated protein-targeted strong or covalently binding precursor compounds and radiotracers

A precursor compound and a radioligand for cancer diagnosis and treatment comprises a high-affinity ligand PL for a cancer- associated protein conjugated to a covalent warhead CW for strong or covalent binding to an amino acid sidechain of the cancer-associated protein and a chelator Ch for complexation of a radioisotope or a leaving group LR for substitution with a radioisotope, wherein the covalent warhead CW is configured for quasi-covalent ionic binding using a sulfonic acid group or for covalent binding using a sulfur fluoride exchange (SuFEx) group, a benzotriazole or N-methyl-N- arylmethanesulfonamide leaving group or a malolactone group for strain-release alkylation.
Owner:ZOUNEK ALEXIS NIKOLAI +1

Radioligands for targeting cell surface receptors and uses thereof

Provided is a compound comprising a target binding group that is a peptide, one or more potency enhancing groups, one or more effector groups; and two or more linking groups selected from a direct bond, a cleaving group, at least two linking groups independently selected from a direct bond, a cleavable linker or a non-cleavable linker; and optionally at least one branching group that is at least trivalent. For example, the target binding group is a gastric inhibitory peptide receptor (GIP-R) binding group, a glucagon-like peptide-1 receptor (GLP-1R) binding group or a B7-H3 binding peptide. A radionuclide complex comprising the compound and / or solvate thereof and uses thereof for targeting and / or killing target cells is further provided. For example, the compound includes a compound of Formula I.
Owner:FULL LIFE TECH HK LTD

Radioligand compounds and uses thereof

PCT designated stageWO2026098519A1Radioactive preparation carriersAntineoplastic agentsRadioactive Therapeutic AgentCancer cell
Provided herein are compounds for delivery of one or more radiotherapeutic or radiodiagnostic agents. In some embodiments, the compounds have a radioactive agent binding moiety (RBM) connected to a GRPR binding moiety (GBM) through a linker (RBM-L-GBM), wherein the at least one of L and GBM is optionally substituted with an albumin binding moiety (ABM). In some embodiments, the one or more therapeutic or diagnostic agents are delivered to cancer cells.
Owner:CHENGDU NEW RADIOMEDICINE TECH CO LTD

Dual receptor targeting radioligands and uses thereof

PendingCN120129690ARadioactive preparation carriersSomatostatinsDiseaseCholecystokinin receptor
# imgabs0. The present invention discloses compounds of formula (I) and complexes thereof with radionuclides, which can recognize both the somatostatin type 2 receptor (SSTR2) and the cholecystoxin 2 receptor (CCK2R) and can be used in the diagnosis and treatment of diseases in which either or both receptors are overexpressed.
Owner:FULL LIFE TECH HK LTD

Her2 targeting cyclic peptides and conjugates thereof

Described herein are cyclic peptides targeting human epidermal growth factor receptor 2 (HER2), and their incorporation into compounds for radioligand imaging and therapies, as well as methods and / or uses of such compounds for the imaging, treatment and / or prevention of HER2-implicated diseases and disorders (e.g., cancer).
Owner:NOVARTIS AG

A PET probe conjugated with an SSTR agonist and an inhibitor, and its preparation method and application

The present invention relates to the fields of high molecular heterocyclic compounds and nuclear medicine imaging technology, and particularly relates to a PET probe obtained by coupling an SSTR agonist and an inhibitor, and a preparation method and application thereof. The PET molecular probe comprises a targeting molecule obtained by coupling an SSTR agonist and an inhibitor, a radioisotope, and a linker, and the linker connects the targeting molecule and the radioisotope. The heterodimer obtained by coupling the SSTR agonist and the inhibitor can improve the PET detection sensitivity by increasing the binding affinity with the target through a synergistic effect; has higher specificity and can specifically and efficiently target SSTR for in vivo imaging in a variety of tumor microenvironments; not only makes the distribution of the radioligand more uniform, but also can effectively improve the clinical effect of radionuclide therapy after labeling with therapeutic radionuclides such as <supgt;177< / supgt;Lu. Compared with the prior art, the molecular probe has stronger affinity, higher stability and higher target-to-background ratio; meanwhile, the preparation method of the PET molecular probe is simple and stable, and has good market promotion and application prospects.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

EPHA2 targeting radioligand compounds and methods thereof

PCT designated stageWO2026152137A1DimerChemical compound
Disclosed herein are EphA2 targeting compounds or pharmaceutically acceptable salt or radioactive metal complex thereof, and methods of their use in the treatment of EphA2 positive cancer. In certain embodiments, the compound is a Targefrin monomer or dimer compound complexed with a radiometal, such as lutetium-177. In certain embodiments, the compound is an irreversible covalent binder of EphA2. In certain embodiments, the compound is a cyclic compound.
Owner:RGT UNIV OF CALIFORNIA +2

Method of reducing side effects of targeted radiation therapy and of gadolinium in magnetic resonance imaging with DTPA esters

The present invention relates to methods for reducing off-target toxicity in patients undergoing therapy or diagnostics with systemically administered toxic cations, particularly targeted radioligand therapy and diagnostic magnetic resonance imaging with gadolinium. The invention relates to administering an orally bioavailable ester or other derivative of diethylenetriaminepentaacetic acid (DTP A), such as diethyl-DTPA as a binding agent before or after radiopharmaceutical or toxic cation administration. The binding agent binds circulating unbound radionuclides and their toxic decay products and toxic cations, thereby reducing damage to non-target tissues such as kidneys, salivary glands, and bone marrow.
Owner:CAPTURA BIOPHARMA INC

Radioactive ligand compounds and uses thereof

Provided herein are compounds for the delivery of one or more radiotherapy or radiodiagnostic agents. In some embodiments, the compounds have a radioagent binding moiety (RBM) linked to a GRPR binding moiety (GBM) via a linker (RBM-L-GBM) wherein at least one of L and GBM is optionally substituted by an albumin binding moiety (ABM). In some embodiments, the one or more therapeutic or diagnostic agents are delivered to cancer cells.
Owner:CHENGDU NEW RADIOMEDICINE TECH CO LTD

N-(5-substituted-[(1,3,4-thiadiazolyl) or (1,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use

The present application discloses specific compounds of Formula (I) and their use in therapy, in particular, their use as Polymerase Theta (Polθ) inhibitors for the treatment of cancer. The application further discloses the use of a combination comprising a compound of Formula (I) and a radiotherapy or a radioligand in therapy, in particular, the use of specific compounds of Formula (I) as a Polymerase Theta (Polθ) inhibitor in combination with a radiotherapy or a radioligand for the treatment of cancer.
Owner:GILEAD SCIENCES INC

N-(5-substituted-[(1, 3, 4-thiadiazolyl) or (1, 3-thiazolyl)] (substituted) carboxamide compounds, pharmaceutical compositions and methods of preparing amide compounds and uses thereof

The present application discloses specific compounds of formula (I) and their use in therapy, particularly their use as polymerase theta (Pol theta) inhibitors for the treatment of cancer. The present application further discloses the use of a combination comprising a compound of formula (I) and radiation therapy or a radioligand in therapy, in particular the use of a specific compound of formula (I) as a polymerase theta (Pol theta) inhibitor in combination with radiation therapy or a radioligand for the treatment of cancer. # imgabs0 #
Owner:REPARE THERAPEUTICS INC

Method of treating prostate cancer

The present disclosure relates to a method of treating prostate-specific membrane antigen (PSMA)-positive oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor comprising the administration of a therapeutically effective amount of a PSMA-binding radioligand therapeutic (RLT) agent, preferably [177Lu]Lu-PSMA-617 (lutetium (177Lu) vipivotide tetraxetan). Further, the present disclosure relates to radioligand therapy of early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).
Owner:NOVARTIS AG

Combinations of inhibitors of ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) with radiation for cancer therapy

The present invention provides combinations of inhibitors of Ectonucleotide Pyrophosphatase / Phosphodiesterase (ENPP1) with a radiation therapy or a radioligand for the purposes of treating cancer. The invention includes both methods of treatment of cancer with the provided combinations and pharmaceutical compositions comprising such combinations. A preferred ENPP1 inhibitor is SR-8541A; and a preferred radioligand is PluvictoTM.
Owner:STINGRAY THERAPEUTICS INC

Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases

Provided herein is a dendrimer complex comprising a 2-deoxyglucose (2DG) dendrimer and a neuroactive agent conjugated to an outer surface of the dendrimer. The dendrimer complex may further include one or more imaging agents and / or radioligands conjugated to an outer surface of the dendrimer. Such complexes are useful in methods for detecting or treating neurological diseases or disorders.
Owner:WASHINGTON STATE UNIVERSITY +1

Chimeric radiopharmaceuticals targeting proton sensing receptor GPR4

The present invention relates to a compound of formula (0-a) or a pharmaceutically acceptable salt thereof. The compounds of the invention bind to proton sensing G protein coupled receptor type 4 (GPR4) and include a linker and a chelating agent, which may include a radioligand. These compounds of the invention are particularly useful in imaging and in the treatment of solid tumors. And (0-a).
Owner:AMPHILIX AG +1